<!DOCTYPE html><!-- Last Published: Tue Jan 07 2025 15:55:23 GMT+0000 (Coordinated Universal Time) --><html data-wf-domain="www.cambrianbio.com" data-wf-page="65e8fe9201c0e422942549b6" data-wf-site="600be113c4111047016de64a" lang="en" data-wf-collection="65e8fe9201c0e42294254ab2" data-wf-item-slug="the-secret-cambrian-bio-master-plan-to-build-drugs-to-treat-aging-just-between-you-and-me"><head><meta charset="utf-8"/><title>cambrian Bio</title><meta content="width=device-width, initial-scale=1" name="viewport"/><link href="https://cdn.prod.website-files.com/600be113c4111047016de64a/css/cambrian-dev.webflow.0733b0f40.min.css" rel="stylesheet" type="text/css"/><script type="text/javascript">!function(o,c){var n=c.documentElement,t=" w-mod-";n.className+=t+"js",("ontouchstart"in o||o.DocumentTouch&&c instanceof DocumentTouch)&&(n.className+=t+"touch")}(window,document);</script><link href="https://i0.wp.com/www.kibs.co.ke/wp/wp-content/uploads/2023/10/kibs-logo-02.png?fit=120,85&amp;ssl=1" rel="shortcut icon" type="image/x-icon"/><link href="https://cdn.prod.website-files.com/600be113c4111047016de64a/600be12d2137ed834d86305c_webclip.png" rel="apple-touch-icon"/><script async="" src="https://www.googletagmanager.com/gtag/js?id=G-Y7NNGFHMFL"></script><script type="text/javascript">window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);}gtag('js', new Date());gtag('config', 'G-Y7NNGFHMFL', {'anonymize_ip': false});</script><meta name="pinterest" content="nopin" />
<meta name="twitter:card" content="summary_large_image">

<!-- CUSTOM STYLE -->
<style>
html{-webkit-font-smoothing:antialiased;-moz-font-smoothing:antialiased;-o-font-smoothing:antialiased}
body{overscroll-behavior:none;-webkit-tap-highlight-color:transparent}
input,select,textarea{appearance:none;-moz-appearance:none;-webkit-appearance:none}
  
@media screen and (max-width:767px){
  .modal{display:block}
  .modal .c-660{height:-webkit-fill-available}
  .modal .abs-shadow-card{display:none}
  .modal h3{font-size:1.75em}
  }
</style>
<!-- END CUSTOM STYLE -->

<style>
.footer .s:first-child{background:linear-gradient(360deg, #1C5356 0%, #164067 100%)}
.footer .s:last-child{background-color:#1C5356}
.menu{background-image:linear-gradient(180deg,#1c5356,#164067)}
</style>
</head><body><div class="no w-embed"><style>
a{color:inherit}
.notif-wrap ~ .nav{position:relative!important;transform:none!important}
.nav-wrap.with-notif{transform:none!important}
input:valid{border-color:#36c}
.w-form-done p{font-weight:500!important}
.w-form-fail{padding:1em;border-radius:10px;font-size:1em;text-align:center;margin-top:1em;font-weight:400;letter-spacing:-0.02em}
.row:first-child,.row-team:first-child,.pipeline .w-dyn-item:first-child .grid,.rt.preview p:first-child{margin-top:0}
.link-social:last-child{margin-right:0}
.tr{pointer-events:none}
.btn:not(.btn-blue):not(.btn-maroon):not(.btn-upload){background:linear-gradient(90deg, #109E5A 0%, #3366CC 100%)}
.abs svg{position:absolute;left:0;top:0;right:0;bottom:0;width:100%;height:auto}
.abs.abs-bg-bot svg{top:auto}
.abs.abs-footer svg,.c-404 svg{height:100%}
.s-404{max-height:-webkit-fill-available}
.cta p{display:inline-block;font-weight:500;line-height:1.4}
.cta:hover .cta-arrow,.cta:focus .cta-arrow,.link-block:hover .cta-arrow,.link-block:focus .cta-arrow{transform:translateX(.25em)}
.cta:hover .cta-arrow.cta-arrow-inverse,.cta:focus .cta-arrow.cta-arrow-inverse{transform:translateX(-.25em)}
.clamp{overflow:hidden;display:-webkit-box;-webkit-box-orient:vertical;-webkit-line-clamp:3}
.clamp.clamp2{-webkit-line-clamp:2}
.item::after{content:"";background:radial-gradient(circle at 50%,#d8a76e,#f8f0e5);display:block;position:absolute;bottom:0;width:100%;height:1px}
.link-block .cta{transition:opacity 500ms}
.link-block:hover .cta,.link-block:focus .cta,.link-external:hover ~ a .cta,.link-external:focus ~ a .cta{opacity:60%}
.rt blockquote + h6{color:#fff;position:relative;bottom:7em;margin-bottom:-1em}
.rt blockquote + h6 em{font-weight:300;color:#D8A76E;margin-left:1.4em}
.rt figure,.rt .w-embed{margin:3.75em 0}
.rt figure:last-child,.rt .w-embed:last-child{margin-bottom:0}
.rt figure, .rt .w-embed{border-radius:.938em;-webkit-mask-image:-webkit-radial-gradient(white, black)}
.rt figure.w-richtext-figure-type-image,.article img{border-radius:.625em}
.s-privacy .rt a{color:#b1c3e8}
.bg{transform:scale3d(1,1,1);transform-style:preserve-3d}
.link-qa:hover .bg,.link-qa:focus .bg,.link-external:hover ~ .link-qa .bg,.link-external:focus ~ .link-qa .bg{transform:scale3d(1.025,1.025,1)}
.link-qa:hover .btn,.link-qa:focus .btn{filter:brightness(120%);-webkit-filter:brightness(120%)}
.featured .w-dyn-list, .featured .w-dyn-items,.featured .w-dyn-item,.featured .link-qa{height:100%}
.w-file-upload-default,.w-file-upload-uploading{height:3.176470588235294em;display:block}
.w-file-upload-file-name{font-size:inherit}

@media screen and (max-width:479px){
.link-footer:not(:first-child){margin-right:0}
.rt blockquote + h6,.rt blockquote + h6 em{margin-left:0!important}
.rt blockquote + h6{bottom:6em!important;margin-bottom:-3em!important}
.rt blockquote + h6 em{display:block}
.link-qa img{transform:none!important}
.link-qa{color:#F8F0E5!important}
.s1-home,.s1-about,.s1-pipeline,.s1-science{max-height:none!important}
.s1.s1-team{max-height:-webkit-fill-available!important}
.link-contact .btn{width:100%;text-align:center}
.s1{max-height:-webkit-fill-available}
}
@media screen and (min-width:480px){.abs-qa{background-color:transparent!important}}
@media screen and (max-width:767px){
.rt figure,.rt .w-embed{margin:2.5em 0}
.link-team h3{font-size:1.5em}
.rt h2:first-child{margin-top:1.5em}
.card-modal{min-height:-webkit-fill-available}
}
@media screen and (min-width:768px) and (max-width:991px){.s1{max-height:-webkit-fill-available}}
@media screen and (max-width:991px){
.rt blockquote + h6{margin-left:60px;bottom:4.5em;margin-bottom:-1.5em}
.rt blockquote + h6 em{margin-left:1em}
.item .pc.pc-4{margin-top:.2em}
}
@media screen and (min-width:992px){
.s.s1:not(.s1-team){height:calc(100vh + 1vw)}
.s.s1.s1-about{height:calc(100vh + 5vw)}
.s.s1.s1-science{height:calc(100vh + 2vw)}
.row-team:nth-child(3) .grid{-ms-grid-columns:1fr 1fr 1fr 1fr;grid-template-columns:1fr 1fr 1fr 1fr}
.row-team:nth-child(3) h3{font-size:1.25em;font-weight:500}
.menu{background:none!important}
.grid-qa-2 .w-dyn-item:first-child{display:none}
}
@media screen and (min-width:992px) and (max-width:1180px){
.rt blockquote + h6{left:2.75em}
.rt blockquote{margin-left:-1.5em;margin-right:-1.5em}
.c1-contact{padding-top:30px}
.left-110{padding-left:0}
.right-110{padding-right:0}
.c2-contact .left-110{padding-left:3em}
.c2-contact .right-110{padding-right:3em}
.grid.grid-pipeline{font-size:1.2vw}
}
@media screen and (min-width:992px) and (max-width:1360px){body{font-size:14px}}
@media screen and (min-width:992px) and (max-width:1360px){.p-17.p-pipeline-phase.categ{font-size:16px}}
@media screen and (min-width:1792px){
.grid.grid-gap-143{grid-column-gap:8.9375em}
.left-110{padding-left:6.875em}
.right-110{padding-right:6.875em}
}
@media screen and (min-width:2200px){body{font-size:18px}}
</style></div><div class="tr" data-ix="tr"></div><div data-collapse="medium" data-animation="default" data-duration="800" data-easing="ease-out-expo" data-easing2="ease-out-expo" data-w-id="710a0016-3feb-10ed-f3e7-f258a52639cb" role="banner" class="s nav w-nav"><nav class="c"><div class="logo"><a href="../index.html" aria-label="home" class="w-inline-block"><div class="w-embed"><svg xmlns="http://www.w3.org/2000/svg" width="7.1875em" height="1.25em" viewBox="0 0 115 20" fill="currentColor"><path d="M104.144 7.712a5.74 5.74 0 0 1 3.918-1.489 6.14 6.14 0 0 1 2.638.589c.823.389 1.543.956 2.107 1.657.836 1.029 1.28 2.327 1.28 4.518v6.226h-2.641v-6.377c0-1.626-.304-2.382-.776-2.951a3.44 3.44 0 0 0-1.199-.91c-.464-.213-.971-.322-1.484-.32a4.92 4.92 0 0 0-2.083.495 4.79 4.79 0 0 0-1.657 1.327v8.736h-2.641V6.496h2.557l-.019 1.216zM36.15 6.559V7.78c1.04-.948 2.409-1.48 3.833-1.489.881-.005 1.752.182 2.549.547s1.501.898 2.06 1.562a6.54 6.54 0 0 1 2.246-1.577c.855-.364 1.781-.545 2.714-.532a6.04 6.04 0 0 1 2.569.552 5.89 5.89 0 0 1 2.068 1.584c.804.975 1.192 2.218 1.192 4.359v6.49h-2.637V12.38c0-1.303-.276-2.004-.748-2.546a3.2 3.2 0 0 0-1.098-.815c-.423-.191-.882-.291-1.347-.291a5.49 5.49 0 0 0-2.187.497 5.36 5.36 0 0 0-1.787 1.325 10.14 10.14 0 0 1 .234 2.236v6.49h-2.637V12.38c0-1.303-.28-2.004-.753-2.546-.315-.35-.703-.63-1.139-.821s-.908-.288-1.386-.286c-.709.03-1.403.209-2.035.523s-1.188.757-1.63 1.299v8.727H33.59V6.559h2.557zM9.817.001c1.33-.014 2.648.238 3.874.741a9.71 9.71 0 0 1 3.25 2.183L15.754 4.1a.95.95 0 0 1-1.225.082C13.187 3.147 11.528 2.58 9.817 2.57c-3.974 0-7.054 3.088-7.054 7.169 0 4.277 3.165 7.174 7.302 7.174 1.891-.034 3.697-.774 5.044-2.068a.95.95 0 0 1 1.257 0l1.253 1.116c-.915 1.092-2.067 1.974-3.373 2.582a10.03 10.03 0 0 1-4.181.934C4.277 19.481 0 15.341 0 9.739 0 4.277 4.207.001 9.817.001zm69.715 7.87a.85.85 0 0 1-.069.335.87.87 0 0 1-.196.283c-.084.081-.183.145-.293.188s-.227.065-.345.064a4.62 4.62 0 0 0-2.202.582 4.47 4.47 0 0 0-1.631 1.554v8.335h-2.641V6.496h2.557v1.512a4.9 4.9 0 0 1 1.774-1.254 5.02 5.02 0 0 1 2.158-.376c.297-.002.594.016.888.055v1.439zM82.421.269a1.79 1.79 0 0 1 .672.129 1.75 1.75 0 0 1 .569.37 1.7 1.7 0 0 1 .38.555 1.66 1.66 0 0 1 .132.654 1.64 1.64 0 0 1-.137.646 1.68 1.68 0 0 1-.382.545 1.73 1.73 0 0 1-.568.359 1.76 1.76 0 0 1-.666.117 1.73 1.73 0 0 1-.663-.12 1.69 1.69 0 0 1-.562-.363 1.66 1.66 0 0 1-.372-.548 1.61 1.61 0 0 1-.123-.646 1.64 1.64 0 0 1 .124-.648c.085-.206.211-.393.371-.552a1.7 1.7 0 0 1 .561-.369 1.76 1.76 0 0 1 .664-.13zm-1.304 6.226h2.641v12.717h-2.641V6.496zm-52.512.001v8.736a4.49 4.49 0 0 1-1.57 1.322c-.621.316-1.31.487-2.011.5-.569.01-1.134-.092-1.663-.298a4.27 4.27 0 0 1-1.412-.905c-.404-.391-.724-.856-.94-1.369s-.325-1.063-.319-1.618c0-2.218 1.58-4.195 3.702-4.195a3.19 3.19 0 0 1 1.575.355.96.96 0 0 0 .584.11c.202-.026.389-.116.534-.255l1.402-1.366a6.24 6.24 0 0 0-3.885-1.284c-1.12-.013-2.222.267-3.193.811-1.031.602-1.883 1.456-2.471 2.476s-.894 2.174-.885 3.344c-.013 1.164.287 2.311.872 3.327a6.74 6.74 0 0 0 2.457 2.462 6.82 6.82 0 0 0 3.272.838 6.09 6.09 0 0 0 4.03-1.435v1.166h2.552V6.496h-2.632zm67.461-.119V15.1c-.412.553-.949 1.005-1.571 1.321a4.63 4.63 0 0 1-2.01.501 4.36 4.36 0 0 1-1.663-.3 4.27 4.27 0 0 1-1.412-.906 4.15 4.15 0 0 1-.939-1.37 4.06 4.06 0 0 1-.319-1.618c0-2.218 1.585-4.195 3.707-4.195.546-.017 1.088.106 1.571.355a.96.96 0 0 0 .584.11c.202-.026.389-.116.534-.255l1.402-1.366c-1.005-.74-2.211-1.178-3.469-1.259a6.6 6.6 0 0 0-3.609.803 6.79 6.79 0 0 0-2.474 2.473c-.589 1.021-.895 2.173-.887 3.344a6.51 6.51 0 0 0 .872 3.329c.585 1.016 1.434 1.864 2.461 2.46a6.81 6.81 0 0 0 3.272.838c1.477.022 2.911-.489 4.025-1.435v1.166h2.552V6.377h-2.627zm-28.978.656c-.971-.544-2.073-.824-3.193-.811a6.15 6.15 0 0 0-3.922 1.366l1.309 1.339a.94.94 0 0 0 .53.274.96.96 0 0 0 .592-.096 3.34 3.34 0 0 1 1.543-.373c2.211 0 3.861 1.904 3.861 4.099.006.554-.103 1.104-.319 1.616s-.535.978-.938 1.369a4.27 4.27 0 0 1-1.411.905 4.36 4.36 0 0 1-1.661.3c-.702-.012-1.391-.182-2.014-.498a4.49 4.49 0 0 1-1.572-1.323V0h-2.636v19.212h2.58v-1.166c1.113.947 2.547 1.458 4.025 1.435a6.83 6.83 0 0 0 3.272-.838c1.027-.596 1.875-1.445 2.46-2.461a6.52 6.52 0 0 0 .873-3.328c.007-1.173-.301-2.328-.894-3.349a6.81 6.81 0 0 0-2.486-2.472z"/></svg></div></a></div><nav role="navigation" id="menu" class="menu w-nav-menu"><div class="menu-inner"><div class="no-tb"></div><div class="center"><a href="../about.html" tabindex="0" class="navlink">About</a><a href="../science.html" tabindex="0" class="navlink">Science</a><a href="../pipeline.html" class="navlink">Pipeline</a><a href="../team.html" class="navlink">Team</a><a href="../careers-page.html" class="navlink">Careers</a><a href="../news-and-publications.html" class="navlink">News &amp; Publications</a><a href="../blogs.html" class="navlink">Blog</a></div><div class="right"><a role="button" href="../contact.html" target="_blank" class="btn btn-sm w-button">Contact</a></div></div></nav><div class="menu-btn w-nav-button"><div class="menu-bar menu-bar-top"></div><div class="menu-bar menu-bar-mid"></div><div class="menu-bar menu-bar-bot"></div></div></nav></div><main class="main"><section class="s s1-post s1-publications"><div class="abs abs-bg-bot larger-tb w-embed"><svg xmlns="http://www.w3.org/2000/svg" width="1792" height="334" viewBox="0 0 1792 334" fill="none"><mask id="dividerpost1" mask-type="alpha" maskUnits="userSpaceOnUse" x="0" y="0" width="1792" height="334"><path fill="#c4c4c4" d="M0 0h1792v334H0z"/></mask><g mask="url(#dividerpost1)"><path d="M0 318h856.534c37.3 0 73.262-13.897 100.869-38.979l83.697-76.042c27.6-25.082 63.57-38.979 100.87-38.979H1792v178.519H0V318z" fill="#fff"/><mask id="dividerpost2" mask-type="alpha" maskUnits="userSpaceOnUse" x="-1" y="69" width="1784" height="197"><path d="M-1 69h1784v197H-1V69z" fill="#c4c4c4"/></mask><g mask="url(#dividerpost2)"><path fill-rule="evenodd" d="M993.966 69c-34.19 0-67.162 12.679-92.515 35.576l-75.905 68.549c-25.102 22.669-57.745 35.222-91.595 35.222H109v1.369h641.942a138.04 138.04 0 0 0 92.516-35.575l75.904-68.55a136.67 136.67 0 0 1 91.598-35.221h743.89V69H993.966zm41.284 27.313a137.79 137.79 0 0 0-92.546 35.726l-75.932 68.839c-25.11 22.765-57.765 35.37-91.628 35.37H149.968v1.375h642.173c34.203 0 67.186-12.732 92.549-35.725l75.932-68.839c25.111-22.765 57.768-35.37 91.628-35.37h744.16v-1.375h-761.16zm42.16 27.906c-34.2 0-67.19 12.678-92.55 35.575l-75.932 68.55c-25.111 22.669-57.766 35.221-91.629 35.221H192.123v1.37h642.174c34.203 0 67.186-12.679 92.549-35.576l75.934-68.549c25.11-22.669 57.76-35.222 91.63-35.222h744.15v-1.369h-761.15z" fill="url(#dividerpost3)"/></g></g><defs><linearGradient id="dividerpost3" x1="1419.62" y1="22.93" x2="156.858" y2="209.701" gradientUnits="userSpaceOnUse"><stop stop-color="#68a3a7" stop-opacity="0"/><stop offset=".322" stop-color="#68a3a7"/><stop offset=".535" stop-color="#4978a2"/><stop offset="1" stop-color="#4978a2" stop-opacity="0"/></linearGradient></defs></svg></div><div class="c c-890"><a href="../blogs.html" class="cta w-inline-block"><div class="cta-arrow cta-arrow-inverse w-embed"><svg xmlns="http://www.w3.org/2000/svg" width="0.5em" height="0.875em" viewBox="0 0 8 14" fill="none"><path d="M7 13L1 7L7 1" stroke="currentColor" stroke-linecap="round" stroke-linejoin="round"/></svg></div><p class="p-17">Back</p></a></div></section><section class="s s-120 white"><div class="c c-890"><div class="share"><div class="flex-vertical flex-right article-page"><a data-social="twitter" href="the-secret-cambrian-bio-master-plan-to-build-drugs-to-treat-aging-just-between-you-and-me.html#" class="icon-twitter w-inline-block"><div class="icon-2 article-page-icons w-embed"><svg xmlns="http://www.w3.org/2000/svg" width="50" height="50" viewBox="0 0 50 50" fill="none">
<rect width="50" height="50" rx="24" fill="currentColor"/>
<path d="M35.6451 20.4079C35.6451 20.6522 35.6451 20.8964 35.6451 21.1057C35.6451 28.328 30.1302 36.6667 20.0779 36.6667C16.9714 36.6667 14.1093 35.7595 11.666 34.2244C12.0849 34.2593 12.5386 34.2942 12.9575 34.2942C15.5055 34.2942 17.8789 33.4219 19.7637 31.9565C17.3554 31.9216 15.3309 30.3167 14.6678 28.1535C15.0168 28.2233 15.3309 28.2582 15.7149 28.2582C16.2035 28.2582 16.6922 28.1884 17.1459 28.0488C14.6329 27.5604 12.748 25.3623 12.748 22.7107C12.748 22.6758 12.748 22.6758 12.748 22.6409C13.481 23.0596 14.3187 23.3038 15.2262 23.3387C13.7603 22.3618 12.7829 20.6871 12.7829 18.7681C12.7829 17.7563 13.0622 16.8143 13.5159 16.0118C16.2035 19.3264 20.2524 21.4895 24.7899 21.7338C24.6852 21.35 24.6503 20.8964 24.6503 20.4777C24.6503 17.4423 27.0936 15 30.1302 15C31.7009 15 33.132 15.6629 34.1093 16.7096C35.3658 16.4654 36.5177 16.0118 37.5997 15.3838C37.1808 16.6747 36.3082 17.7214 35.1913 18.4192C36.3082 18.2797 37.3554 18.0005 38.3327 17.547C37.6346 18.6634 36.7271 19.6404 35.6451 20.4079Z" fill="white"/>
</svg></div></a><a data-social="linkedin" href="the-secret-cambrian-bio-master-plan-to-build-drugs-to-treat-aging-just-between-you-and-me.html#" class="icon-linkedin w-inline-block"><div class="icon-2 article-page-icons w-embed"><svg width="50" height="50" viewBox="0 0 50 50" fill="none" xmlns="http://www.w3.org/2000/svg">
<rect width="50" height="50" rx="25" fill="currentColor"/>
<path d="M35.5839 33.9926C34.3059 33.9622 33.0583 33.9622 31.7803 33.9926C31.5065 33.9926 31.4456 33.9318 31.4456 33.6579C31.4456 31.4062 31.4456 29.1241 31.4456 26.8723C31.4456 26.3551 31.4152 25.8378 31.263 25.3509C30.8066 23.7686 28.9809 23.1905 27.6725 24.2555C26.9726 24.8032 26.6987 25.5639 26.6987 26.4768C26.6987 28.6068 26.6987 30.7368 26.6987 32.8668C26.6987 33.1406 26.6683 33.4145 26.6987 33.7188C26.7292 33.9622 26.6075 34.0231 26.3945 33.9926C25.086 33.9926 23.808 33.9926 22.4996 33.9926C22.2562 33.9926 22.1953 33.9318 22.1953 33.6884C22.2257 31.7714 22.2257 29.8544 22.2257 27.9069C22.2257 25.5335 22.2257 23.1601 22.1953 20.8171C22.1953 20.5432 22.2562 20.4823 22.4996 20.4823C23.808 20.4823 25.086 20.4823 26.3945 20.4823C26.6379 20.4823 26.6987 20.5432 26.6987 20.7866C26.6987 21.2735 26.6987 21.7603 26.6987 22.3385C26.79 22.2472 26.8205 22.2168 26.8509 22.1863C28.0376 20.4519 29.7112 19.9651 31.689 20.2693C33.9712 20.6345 35.4318 22.2168 35.7969 24.6511C35.8882 25.2292 35.9186 25.8073 35.9186 26.3855C35.9186 28.8198 35.9186 31.2236 35.9186 33.6579C35.9186 33.9014 35.8578 33.9926 35.5839 33.9926Z" fill="white"/>
<path d="M19.7621 27.2376C19.7621 29.3676 19.7621 31.4976 19.7621 33.6276C19.7621 33.9014 19.7012 33.9927 19.4274 33.9927C18.1494 33.9623 16.8714 33.9927 15.5933 33.9927C15.3499 33.9927 15.2891 33.9319 15.2891 33.6884C15.2891 29.398 15.2891 25.0771 15.2891 20.7867C15.2891 20.5737 15.3499 20.4824 15.5933 20.4824C16.9018 20.4824 18.2102 20.4824 19.5186 20.4824C19.7925 20.4824 19.8229 20.5737 19.8229 20.8171C19.7621 22.9471 19.7621 25.0771 19.7621 27.2376Z" fill="white"/>
<path d="M19.9744 16.9528C19.6701 18.1699 18.4225 18.8698 16.9924 18.6264C15.471 18.3829 14.619 16.8919 15.1667 15.4313C15.5318 14.5185 16.4143 13.9708 17.5401 14.0012C19.2441 13.9708 20.37 15.3401 19.9744 16.9528Z" fill="white"/>
</svg></div></a><a r-copy-to-clipboard="url" href="the-secret-cambrian-bio-master-plan-to-build-drugs-to-treat-aging-just-between-you-and-me.html#" target="_blank" class="w-inline-block"><div data-w-id="c5bb57b1-161d-3bbb-9708-83a2c5f36c4d" class="icon-2 article-page-icons w-embed"><svg width="50" height="50" viewBox="0 0 50 50" fill="none" xmlns="http://www.w3.org/2000/svg">
<circle cx="25" cy="25" r="25" fill="currentColor"/>
<path d="M38.0661 23.8184L29.3967 29.8825C28.0711 30.8098 26.2503 29.8614 26.2504 28.2436L26.2504 25.8333C26.2504 25.8333 19.7921 25.625 17.0837 28.75C14.3752 31.875 13.3338 35 13.3338 35C13.3338 35 12.9172 27.0833 17.0837 22.5C21.2501 17.9167 26.2504 19.5 26.2504 19.5L26.2504 16.2801C26.2503 14.6741 28.0478 13.7231 29.3755 14.6267L38.045 20.5261C39.2023 21.3137 39.2133 23.016 38.0661 23.8184Z" fill="white"/>
</svg></div></a><div class="div-block-9"><div class="copied-text noshow">Copied!</div></div></div></div><article class="article"><h1 class="h8">The Secret cambrian Bio Master Plan to Build Drugs to Treat Aging (just between you and me)</h1><div class="date-time"><div class="margin-right-40"><div class="margin-right-4"><div class="flex-center"><p class="regular">10 mins to read</p></div></div></div><div class="margin-right-4"><p class="paragraph-2">January 6, 2022</p></div></div><div class="author"><div class="margin-right-40"><div class="margin-right-4"><div class="flex-center"><p class="author-1">Author:</p><p class="author-2">James Peyer, PhD; CEO, cambrian Bio</p></div></div></div></div><p class="paragraph-13 w-dyn-bind-empty"></p><div class="blog-post w-richtext"><p><em>Background: cambrian Bio, which I started in 2019 with my co-founder Christian Angermayer, recently announced that we raised $100M from a fantastic group of investors in a Series C round, bringing our funding to around $160M in the last two years. Over 100 scientists, company builders, and drug developers are working together to create the first medicines to slow human aging.</em></p><p>If you ask a doctor what a healthy 60-year-old should do to optimize their health, the only answer well-supported by clinical data today is &quot;diet and exercise.&quot; I&#x27;m a big fan of good diet and exercise, but even a vegan yogi has less than a 10% chance of making it to their 100th birthday. Medicine can do better. The last decade has seen our understanding of how and why we age expand dramatically. It&#x27;s time to start putting that knowledge to use to help people everywhere live healthier longer.<br/></p><p>Our mission at cambrian is to create medicines that keep people healthy instead of treating symptoms after they get sick: intervening before a person becomes a patient. <br/></p><p>To make this mission a reality, cambrian is currently developing more than 15 novel therapies (aka drugs) that repair key types of molecular or cellular damage that gradually weaken and age our bodies. By targeting these causes of aging, each of our new medicines has the potential to extend human healthspan, the years of life spent in good health.<br/></p><p>Despite the enormous benefits to individuals and society from medicines that could keep people healthier for longer, the development of geroprotectors (aka drugs that prevent age-related decline) accounts for a tiny fraction (less than 1%) of research dollars. The most common reason cited for this under-investment is that “aging” is not a disease, therefore you can’t run a trial to “slow aging.”<br/></p><p>This simplistic statement misses the mark in a few ways. The real challenges we need to overcome are more nuanced. They are: (1) multi-disease prevention (i.e., “aging”) trials are risky, expensive, and slow; and (2) we don’t have the biomarker needed to run cost-effective prevention trials in healthy people.<br/></p><p>cambrian’s strategy tackles both of these key challenges with what I call our ‘Secret Master Plan’. Our plan has three stages: get approval for newly developed geroprotectors as treatments for existing diseases causing acute suffering to patients today. Then, when it’s clear these drugs are safe, effective, and valuable, do the large and expensive trials to show that these medicines slow aging in at-risk (often older) people. Finally, we will use the huge amounts of data gathered from rigorous and controlled clinical trials to approve geroprotectors using a surrogate biomarker of multi-morbidity risk (more on this in a bit) to help people in good health stay that way. <br/></p><p>Longevity outsiders criticize any preventative medicine approaches because the clinical trials are long and expensive. Longevity insiders criticize our approach of starting with currently recognized diseases because they want to run aging studies now. Both of them are wrong. Prevention studies are both feasible and worth doing, but they can only start once the safety and commercial value of a drug has been established. Here’s how the Master Plan will work.<br/></p><p><strong>Stage 1. Show that new geroprotective drugs are safe and effective at treating existing diseases.</strong><br/></p><p>cambrian is starting by applying breakthroughs in our understanding of what causes us to age and decline to make new drugs that treat multiple diseases.<br/></p><p>Each new cambrian medicine will undergo clinical trials in a well-recognized indication (a disease or condition) where patients need better treatments. Regulators, doctors, and patients want to get these new medicines approved quickly to give suffering people better quality of life. It turns out that if a drug can improve one or more of the fundamental biological processes that break down as we age, we can usually find at least one disease that is caused by the same biological process going haywire. Once we identify this disease, we test whether our geroprotector can serve as a treatment for those patients. Clinical trials for these indications can be small and focused which makes it much faster and cheaper for us to demonstrate safety and efficacy with our new drugs. We also get to help people suffering with debilitating and often neglected conditions. We love a win/win situation. <br/></p><p>Because disease trials are the first “step” on the path of a medicine to becoming an approved multi-disease preventative, we call it a “stepping stone indication.” The stepping stone indications targeted by our medicines are each multi-billion dollar per year markets. That’s why a drug that demonstrated efficacy in clinical trials is worth billions. For most biotech and pharma companies, this is their entire goal – make a better treatment for an existing disease – but for us this is only the first step. <br/></p><p>After achieving a few stepping stones, we will be on solid footing (both scientific and financial) to jump into the more challenging world of prevention.<br/></p><p><strong>Stage 2. Show that geroprotectors prevent disease in “at risk” people.</strong><br/></p><p>Once we show that a drug is safe, effective and that it targets a specific cause of aging in the stepping stone trials, we can start using our understanding of the causes of aging to prevent diseases before people get sick.<br/></p><p>To see an effect of a geroprotective drug in a prevention clinical trial, some people in the placebo arm of a clinical trial must get sick or die while those in the experimental arm of the trial stay healthy. The healthier the people in the trial are, the more people need to be in the trial and the longer it needs to run. Trial size and duration are the two leading drivers of clinical trial costs which means that preventative trials in healthy people must be large, long, and very expensive. <br/></p><p>Because a geroprotection study of healthy people in middle age would take decades, our first preventative studies will involve older people at high risk for developing the major diseases of aging. A well-designed trial will deliver a clear yes/no answer on whether a drug reduces risk of multiple diseases in 3 to 5 years. Still a long time, but worth it to show that a geroprotector can extend healthspan in humans.<br/></p><p>Philanthropically funded clinical trials are already contemplating this approach, most notably the TAME Trial which proposes to use metformin (an off-patent diabetes medicine that extends healthspan in mice) in elderly individuals to prevent them from developing new morbidities. The bar for new drugs still under patent will be higher than for old drugs like metformin, but new drugs intentionally designed to maximize longevity effects and increase safety will work much better than the field’s first coincidental discoveries like metformin and rapamycin. <br/></p><p>A multi-disease preventative taken by at-risk elderly people would be the best-selling drug of all time. In 2030, a drug approved only for people 75 and older would have a market size of over $30 billion per year even if that drug costs less than $1,000 annually (way cheaper than most other drugs and less than a cup of coffee per day in New York). The impact of such a drug would be priceless.<br/></p><p><strong>Stage 3. Use a biomarker surrogate endpoint to approve geroprotectors for everyone.</strong><br/></p><p>Showing that a drug works to slow aging in an elderly population is an excellent milestone, but geroprotectors will work best if we treat healthy people before they show any symptoms of aging. This hypothesis is supported by animal studies of geroprotectors, where there are diminishing returns on both lifespan and healthspan gains the later an animal is started on preventative treatment.<br/></p><p>To approve geroprotectors for younger, healthier people, there must be a clear way of determining in a randomized, placebo controlled trial that the geroprotector is helping, even if people that are getting the placebo aren’t dying or getting sick in large numbers. For this, we need to measure something about the person that predicts whether they will get sick. We call this a surrogate biomarker.<br/></p><p>For regulators to accept a biomarker as a surrogate endpoint it must meet three criteria:</p><ul role="list"><li>Biomarker predicts morbidity and mortality in large datasets (we have more than a dozen ‘biological clocks’ that do this),</li><li>Biomarker is improved by drug treatment in placebo controlled clinical trials (we will get the data from both Stages 1 and 2), and </li><li>Whenever the biomarker is improved by a geroprotector in a trial, the risk of illness goes down (we will get the data from Stage 2).</li></ul><p>To do this, we are collecting data for candidate biomarkers in all of cambrian’s trials in both Stage 1 and 2 described above. We also launched a data sharing collective with other nonprofit and for-profit leaders in the field to unite the industry around these goals.<br/></p><p>Once a validated surrogate endpoint for multi-morbidity risk exists, it will be used to run short (1 to 3 year) prevention trials in healthy adults, and drugs could be approved based on their ability to safely improve that biomarker. This is the endgame of the emerging longevity biotech field, and the dream we have for every new medicine that we guide through drug discovery and into its first clinical trials.<br/></p><p><strong>Conclusion. Something old is young again.</strong><br/></p><p>This framework will allow cambrian to test and approve multiple new medicines that proactively treat the molecular and cellular changes underlying the debilitating effects of aging. Much of this will be done for the first time – the medicines will be new, the type of damage they are treating is new, the biomarker is new, and the idea of building a large multi-mechanism prevention framework has not been seen in medicine since the widespread adoption of vaccines.<br/></p><p>The good news is that  the regulatory path that geroprotectors will follow is not new. Every major drug regulator including the US FDA  has already approved preventative drugs. In fact, with a few details altered, the schema I describe here could be a history of the approval of cholesterol-reducing HMG-CoA Reductase Inhibitors (better known as statins with brand names like Crestor and Lipitor, the best-selling drug of all time).<br/></p><p>After their discovery, statins were first tested and approved to treat a rare acute childhood disease: familial hypercholesterolemia (Stage 1). Once the drug was proven safe and effective at lowering cholesterol, trials were run to show the drug could reduce mortality in people at high risk for getting a heart attack (Stage 2). Through these trials, the data showed that LDL cholesterol was a surrogate biomarker, so studies for heart disease prevention that focused just on lowering cholesterol were run in younger, healthier people (Stage 3). One could even argue that statins are the first geroprotective drugs, although they reduce morbidity and mortality from just heart disease, instead of many diseases of aging at once.<br/></p><p>To accomplish cambrian’s mission, we don’t have to reinvent the wheel, but the result – a suite of preventative therapies that can keep people healthy for years or even decades longer – promises to be one hell of a new car.<br/></p><p><strong>So, in short, the master plan is:</strong></p><p><strong>‍</strong>Create drugs that target the causes of aging and show they work to treat acute diseases,<br/>Use these safe effective drugs to reduce risk of death and illness in older people,<br/>Get those drugs approved for everyone using data from earlier trials.</p><p>Don&#x27;t tell anyone.<br/></p></div><p></p></article></div></section><section class="s"></section></main><script src="https://d3e54v103j8qbb.cloudfront.net/js/jquery-3.5.1.min.dc5e7f18c8.js?site=600be113c4111047016de64a" type="text/javascript" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script><script src="https://cdn.prod.website-files.com/600be113c4111047016de64a/js/webflow.0527a82382a637c47b9102f8ac6f9982.js" type="text/javascript"></script><script>
// PAGE TRANSITION
function tr(myLink) {
    return (myLink.host == window.location.host);
}
$('a:not(.w-pagination-next)').each(function() {
  if (tr(this) && (this).href.indexOf('#') === -1) {
  $(this).click(function(e){
  e.preventDefault();
  var moduleURL = jQuery(this).attr("href");
  setTimeout( function() { window.location = moduleURL }, 350 );
  $('.tr').css("opacity", "1");
});
    }
});
  $(window).bind("pageshow", function(event) {
    if (event.originalEvent.persisted) {
        window.location.reload() 
    }
});

// NAV INTERACTIONS
$('.menu-btn').click(function() {
$('.nav').toggleClass('nav-open');
});
  
// LOCK SCROLL - MENU OPEN
(function(){$(".menu-btn").click(function(){$("body").toggleClass("overflow")})}).call(this),function(){var t=document.getElementById("menu"),e=null;t.addEventListener("touchstart",function(t){1===t.targetTouches.length&&(e=t.targetTouches[0].clientY)},!1),t.addEventListener("touchmove",function(n){1===n.targetTouches.length&&function(n){var o=n.targetTouches[0].clientY-e;0===t.scrollTop&&o>0&&n.preventDefault(),t.scrollHeight-t.scrollTop<=t.clientHeight&&o<0&&n.preventDefault()}(n)},!1)}();
</script>


<script>
document.addEventListener('DOMContentLoaded', function() {
    // Select all interactive elements
    var focusableElements = 'a[href], button, input, textarea, select, details, [tabindex]:not([tabindex="-1"])';
    var focusables = document.querySelectorAll(focusableElements);

    // Add a keydown event listener to each focusable element
    focusables.forEach(function(element) {
        element.addEventListener('keydown', function(e) {
            if (e.key === 'Tab') {
                // Prevent the default tab behavior
                e.preventDefault();
                var index = Array.prototype.indexOf.call(focusables, e.target);
                var nextElement = focusables[index + (e.shiftKey ? -1 : 1)];
                if (!nextElement) {
                    nextElement = focusables[e.shiftKey ? focusables.length - 1 : 0];
                }
                nextElement.focus();
            }
        });
    });
});
</script>

<script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.6.0/jquery.min.js" integrity="sha512-894YE6QWD5I59HgZOGReFYm4dnWc1Qt5NtvYSaNcOP+u1T9qYdvdihz0PPSiiqn/+/3e7Jo4EaG7TubfWGUrMQ==" crossorigin="anonymous" referrerpolicy="no-referrer"></script>>

<script>
    function shareToTwitter(btn, link) {
        btn.setAttribute('target', '_blank');
        btn.setAttribute(
            'href',
            `https://twitter.com/share?url=${link}`
        );
    }
      function shareToLinkedIn(btn, link) {
        btn.setAttribute('target', '_blank');
        btn.setAttribute(
            'href',
            `https://www.linkedin.com/sharing/share-offsite/?url=${link}`
        );
    }
    function socialShare(platform, btn, link) {
        if (platform === 'twitter') {
            shareToTwitter(btn, link);
        } else if (platform === 'linkedin') {
            shareToLinkedIn(btn, link);
        }
    }
</script>
<script>
    // social sharing
    const btns = {
        'linkedin': document.querySelector('[data-social="linkedin"]'),
        'twitter': document.querySelector('[data-social="twitter"]')
    }
    const link = window.location.href;
    for (let key in btns) {
        if (btns.hasOwnProperty(key)) {
            socialShare(key, btns[key], link);
        }
    }
</script>

<script>
// CHANGE NAV BACKGROUND ON SCROLL
$(window).scroll(function() {
    $(document).scrollTop() > 0 ? $(".s.nav").css({
        "background":"linear-gradient(180deg,#1c5356,#164067)"
    }) : $(".nav").css({
        "background":"none"
    })
});
</script>

<script src="https://tools.refokus.com/copy-to-clipboard/bundle.v1.0.0.js"></script></body></html>